Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population by Bosch, L.J.W. (Linda) et al.
D
ow
nloaded
from
https://journals.lw
w
.com
/ajg
by
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
3m
R
gP
8K
M
O
yN
+A
kR
kv3X
R
G
vH
V
H
/xH
M
H
4V
X
R
snl5rw
eO
qM
=
on
04/07/2020
Downloadedfromhttps://journals.lww.com/ajgbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3mRgP8KMOyN+AkRkv3XRGvHVH/xHMH4VXRsnl5rweOqM=on04/07/2020
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E.M. Stoop, MD, PhD6, T.R. de Wijkerslooth, MD, PhD7, C.J.J. Mulder, MD, PhD5, C. Rausch, PhD1, E.J. Kuipers, MD, PhD6,
E. Dekker, MD, PhD7, M.J. Domanico, PhD8, G.P. Lidgard, PhD8, B.M. Berger, MD8, M. van Engeland, PhD2, B. Carvalho, PhD1 and
G.A. Meijer, MD, PhD1
INTRODUCTION: We set out to evaluate the performance of a multitarget stool DNA (MT-sDNA) in an average-risk
colonoscopy-controlled colorectal cancer (CRC) screening population. MT-sDNA stool test results were
evaluated against fecal immunochemical test (FIT) results for the detection of different lesions,
including molecularly defined high-risk adenomas and several other tumor characteristics.
METHODS: Whole stool samples (n 5 1,047) were prospectively collected and subjected to an MT-sDNA test,
which tests forKRASmutations,NDRG4 andBMP3promotermethylation, andhemoglobin.Results for
detecting CRC (n 5 7), advanced precancerous lesions (advanced adenoma [AA] and advanced
serrated polyps; n5119), and non-AAs (n5191) were comparedwith those of FIT alone (thresholds of
50, 75, and 100 hemoglobin/mL). AAs with high risk of progression were defined by the presence of
specific DNA copy number events as measured by low-pass whole genome sequencing.
RESULTS: TheMT-sDNA test wasmore sensitive than FIT alone in detecting advanced precancerous lesions (46%
(55/119) vs 27% (32/119), respectively, P < 0.001). Specificities among individuals with
nonadvanced or negative findings (controls) were 89% (791/888) and 93% (828/888) for MT-sDNA
and FIT testing, respectively. A positive MT-sDNA test was associated with multiple lesions (P 5
0.005), larger lesions (P50.03), and lesionswith tubulovillous architecture (P50.04). The sensitivity
of the MT-sDNA test or FIT in detecting individuals with high-risk AAs (n 5 19) from individuals with
low-risk AAs (n 5 52) was not significantly different.
DISCUSSION: In an average-risk screening population, the MT-sDNA test has an increased sensitivity for detecting
advanced precancerous lesions compared with FIT alone. AAs with a high risk of progression were not
detected with significantly higher sensitivity by MT-sDNA or FIT.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B323, http://links.lww.com/AJG/B324
Am J Gastroenterol 2019;114:1909–1918. https://doi.org/10.14309/ajg.0000000000000445
INTRODUCTION
Colorectal cancer (CRC) is the thirdmost common cancer and
is one of the leading causes of cancer-related mortality (1).
Although CRC incidence is increasing, a decrease in mortality
has been observed due to the implementation of CRC
screening and improved therapies (2,3). CRC screening not
only leads to a reduction in morbidity and mortality but also
to a lower CRC incidence when neoplastic lesions can be
detected and removed at a premalignant stage (2). Therefore,
CRC screening is considered cost-effective or even cost-
saving (4).
Currently, colonoscopy is used for opportunistic screening
programs in the United States, whereas in Europe, fecal immu-
nochemical test (FIT) is the first choice for CRC screening in
invitation-based screening programs. Both are considered cost-
effective. Yet, FIT has suboptimal sensitivity for CRC (average
79%) and advanced adenomas (AAs; average 31%), precursor
lesions with an increased risk of progression (5,6).
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We and others have shown that molecular stool tests have the
potential to outperform FIT (7–9). We identified aberrantNDRG4
CpGpromoter hypermethylation as a stool biomarker for the early
CRC detection (7), after which it was incorporated in an FDA-
approved multitarget stool DNA (MT-sDNA) test (Cologuard;
Exact Sciences, Madison, WI). This test contains multiple DNA
targets (NDRG4 and BMP3 hypermethylation and KRAS muta-
tions) and fecal hemoglobin. This MT-sDNA test was clinically
validated in stool samples from almost 10.000 average risk indi-
viduals, where it detected up to 42% of AAs and 92% of CRCs.
These sensitivities provide higher single-application sensitivity
than a commercial FIT for both CRC and AA (10). Although
single-application MT-sDNA specificity is lower than FIT as
generally used in annual population screening, guidelines in the
United States (11) recommend MT-sDNA screening every three
years which has similar specificity to 3 annual FIT applications.
Although most studies focus on the detection of CRC rather
than precursor lesions, it is evident that most room for improving
screening tests lies in more sensitive adenoma detection (12,13).
AAs, defined by histopathological criteria of size, presence of vil-
lous architecture, and/or high-grade dysplasia, have been consid-
ered to be at higher risk of progressing to carcinoma than non-AAs
(14). Detection of AAs is therefore used as an important in-
termediate endpoint in evaluating screening. However, only about
5% of all adenomas will ever progress to cancer (15–17); thus,
ideally, the interventional screening target should be even more
focused. Our research group established an alternative molecular-
defined intermediate endpoint based on specific DNA copy
number aberrations (gain of 8q, 13q, and 20q; loss of 8p, 15q, 17p,
and 18q) that distinguish adenomas at low risk of progression from
adenomas with a high risk of progression and later stage cancers
with a sensitivity of 78% and specificity of 78% (18). These specific
DNA copy number aberrations were found in 25% of the AAs and
also occurred in 3% of non-AAs (19). Moreover, in functional
studies, it was observed that only adenoma organoids that carried
chromosomal instability were able to progress to invasive carci-
nomas (20). These studies indicate a role of copy number alter-
ations in predicting the risk of progression to CRC (16,21).
In this study, we evaluated the performance of an MT-sDNA
test, analyzing aberrant NDRG4 and BMP3 promoter hyper-
methylation, KRAS mutations, and hemoglobin, in archived stool
samples from a Dutch average-risk primary screening population.
Moreover, we compared the sensitivity of MT-sDNA and FIT for
detecting AAs with a high risk and a low risk of progression.
MATERIALS AND METHODS
Study population
Between June 2009 and July 2010, a total of 6,600 asymptomatic
individuals in the regions of Amsterdam and Rotterdam, aged
50–75 years, were randomly selected by the regional municipal
administration registrations and invited for primary colonoscopy
screening. The protocol of this population-based screening pilot
(COlonoscopy or COlonography for Screening [COCOS] trial)
has been described in detail previously (22). The results on par-
ticipation and diagnostic yield of this trial have been published
(23). In short, participation with CT colonography was signifi-
cantly better than with colonoscopy, but colonoscopy identified
significantly more advanced neoplasia per 100 participants (7,8)
than did CT colonography (1,6). The diagnostic yield for ad-
vanced neoplasia per 100 invitees was similar for both strategies
(1.5 per 100 invitees for colonoscopy and 2.0 per 100 invitees for
CT colonography). The trial was registered in the Dutch Trial
Register: NTR1829 (http://www.trialregister.nl). At the time of
the trial, the Netherlands did not have a population-based CRC
screening program, and invitees were screening-naive. Invitees
who had had a full colonic examination in the previous 5 years
(complete colonoscopy, CT colonography, and/or double-
contrast barium enema) were excluded from the screening trial.
Invitees planned for surveillance colonoscopy (personal history
of CRC, colonic adenomas, or inflammatory bowel disease) and
individuals with end-stage disease and a life expectancy of less
than 5 years were also excluded. Ethical approval was obtained
from the Dutch National Health Council (2009/03WBO, Hague,
the Netherlands).
Screening participants allocated to the colonoscopy arm of the
COCOS trial (n 5 1,426) and willing to undergo colonoscopy
were invited to collect 1 sample FIT (OC-Sensor; EikenChemical,
Tokyo, Japan) and 1 whole stool sample before their screening
colonoscopy and before the start of laxative treatment. Sponta-
neously passed stool samples were collected from 1,047 partic-
ipants who completed colonoscopy and had a valid FIT test.
Participants were verbally instructed at the screening center or at
home. Screening participants who agreed to participate gave
written informed consent. The results on the diagnostic accuracy
of the FIT have been published (5). For FIT with threshold 50 ng/
mL, sensitivities were 35% for detecting AA and 88% for CRC
with 91%–93% specificity.
Histology
Excised lesions were assessed by 1 of 2 expert gastrointestinal
pathologists, 1 in each center as described before (23). Lesions
were categorized as non-neoplastic, serrated polyp, adenoma, or
carcinoma (24). Dysplasia was defined as either low grade or high
grade. Advanced precancerous lesions refer to both AA and ad-
vanced serrated polyps (ASPs). An AA was defined as an ade-
noma $ 10 mm or an adenoma with villous histology ($25%
villous) and/or high-grade dysplasia of any size. An ASP was
defined as a serrated or hyperplastic polyp $1 cm and/or a ser-
rated polyp with low- or high-grade dysplasia. Advanced neo-
plasia included ASP, AA, and/or carcinoma.
We adhered to previous histological assessments (23) in the
current study. Because the high sensitivity of the MT-sDNA test
to detect high-grade dysplastic lesions (10) could not be con-
firmed in this study, lesions frompatientswith a single high-grade
dysplastic lesion were rereviewed for the current study. Because
the tissue slides as used for the previous histological assessment
(23) were not available, new slides were used for these revisions.
Colonoscopy
All colonoscopies were performed according to the standard
quality indicators defined by the Society of Gastrointestinal En-
doscopy and recorded on DVD (25). Details of the procedure
have been published (23). The most important quality indicators
were qualifications and colonoscopy experience of the endo-
scopist (.500), adequate bowel preparation (Ottawa bowel
preparation score ,11), colonoscope withdrawal time (.6
minutes), and completeness of the colonoscopy (26). All colo-
noscopies were performed by endoscopists with experience of
more than 1,000 colonoscopies, the median Ottawa bowel prep-
aration score was 5 (interquartile range 3–8), the median net
withdrawal time was 10 minutes (interquartile range 8–15
minutes), and the cecal intubation rate was 99% (5,27).
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FIT
FIT (OC-Sensor, Eiken Chemical, Tokyo, Japan) was performed
by the screening participants before their preparation for
screening colonoscopy. Details of the procedure have been pub-
lished (5). Quantitative FIT values were available for the current
study. Cutoff levels of 50 (FIT50), 75 (FIT75) and 100 (FIT100) ng
hemoglobin (Hb)/mLof buffer, correspondingwith 10, 15, and 20
mg Hb/g of feces, respectively, were considered as regular cutoff
levels for calling a FIT positive or negative.
Stool samples and MT-sDNA test
All stool samples for DNA marker analysis were collected and
processed according to a uniform standard operational procedure
and analyzed at Exact Sciences Laboratory (Madison, WI). Single
spontaneous stool samples were collected into a provided collec-
tion container. Stool stabilizationbuffer (Exact Sciences)was added
to the stool sample by the screening participants immediately after
defecation. The samples were processed in the laboratory with
a final stool:buffer w/v ratio of 1:7 within 72 h after defecation,
separated into aliquots, and stored at280 °C until use. Extraction
and analysis of stool DNAwas performed as described before (10).
The DNA components were measured with quantitative mo-
lecular assays for aberrantly methylated BMP3 and NDRG4 pro-
moter regions and 7 point mutations in KRAS (2 groups of
mutations in theKRASgene in codon12 [referred to asKRAS1]and
codon 13 [referred to as KRAS2]) (10). ACTB was used as a refer-
ence gene for humanDNAquantity, both for themethylation assay
and for the mutation assay (10). Fecal human hemoglobin levels
were available from the previously measured FIT (OC-Sensor)
values (5), and these values were used to calculate the final
MT-sDNA result. As this assay differs from that is included in the
MT-sDNA test as described before (OC FIT-CHEK; Polymedco,
Cortlandt,NY [10]), the hemoglobin levelsmeasuredbyOC-Sensor
were recalculated toOCFIT-CHEKvalues for use in theMT-sDNA
analytic algorithm (data not shown). Quantitativemeasurements of
each marker (DNA and hemoglobin) were incorporated into this
validated, prespecified logistic-regression algorithm, and a re-
gression score (MT-sDNA score)was calculated, with a value of 183
or more, indicating that the MT-sDNA test result was positive (10)
(see Supplementary Methods and Results, Supplementary Digital
Content 1, http://links.lww.com/AJG/B323 and Figure 1, Supple-
mentary Digital Content 2, http://links.lww.com/AJG/B324). Lab-
oratory testing was performed without knowledge of the results of
either the comparator FIT or clinical findings.
Tissue samples
Collection, storage, and use of patient-derived tissue and data
were performed in compliance with the Code for Proper Sec-
ondary Use of Human Tissue in The Netherlands Dutch Feder-
ation of Biomedical Scientific Societies (28). Formalin-fixed
paraffin-embedded tissue blocks from advanced neoplasia from
patients with a valid MT-sDNA test were requested through the
Dutch National Tissue Portal in close collaboration with the
Dutch nationwide network and registry of histopathology and
cytopathology in the Netherlands PALGA (29,30). DNA was
isolated by a column-based method (QIamp DNA microkit;
Qiagen, Hilden, Germany) as described before (31), with few
adaptations for small lesions. These adaptations included a 5-day
incubation period with lysis buffer (ATL buffer, QIAmp; DNA
micro-kit, Qiagen) and freshly added (once every day) proteinase
K (10 mL of 20 ng/mL) (32). Concentrations and purity were
measured on a Nanodrop ND-1000 spectrophotometer (Nano-
dropTechnologies,Wilmington,DE). Tissue samples froma total
of 159 advanced neoplasia from 118 individuals (often two or
more advanced neoplasia present in 1 patient) were retrieved for
molecular analysis.
MT-sDNA test on tissue samples Tissue DNA yields were ade-
quate for analysis in 158 of 159 samples and were assayed for
KRAS mutations aberrant NDRG4 and BMP3 methylation and
ACTB as described before (33). Successful analysis was obtained
for 153 samples.
Low-pass whole genome sequencingAtotalof96AAtissue samples
from non-CRC patients were available for low-pass whole genome
sequencingandgenomewideDNAcopynumber analysis asdescribed
before (19,34). The DNA copy number data are available in the Eu-
ropean Genome-Phenome Archive (EGA; https://www.ebi.ac.uk)
under EGAS00001002952/EGAD00001004078. Three AA samples
fromthisEGAarchivewereexcluded in thecurrent studybecause they
either belonged to patients who have a CRC as most advanced lesion
or were derived from different blocks from the same tumor.
Figure 1. Flowchart of the study design. The upper part indicates the stool
collection derived from the colonoscopy arm of individuals who partici-
pated the COCOS trial. Only individuals who had a complete colonoscopy,
who had a valid FIT result, and who provided a whole stool sample were
included in the biomarker study population. Tissues were collected from
participants with an advanced neoplasia, e.g., CRC, AA, and/or ASP, of
which the numbers and performed analyses are indicated in the lower part.
AA, advanced adenoma; ASP, advanced serrated polyp; COCOS, COlo-
noscopy or COlonography for Screening; CRC, colorectal cancer.
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AAs with at least 2 of 7 cancer-associated events (gain of 8q,
13q, and 20q; loss of 8p, 15q, 17p, and 18q) are defined as high-
risk adenomas (18,19). Individuals with at least 1 high-risk ade-
noma are defined as high risk. When DNA copy number analysis
of 1 or more AAs was missing from an individual with otherwise
low-risk AAs, the individual was excluded from further analyses
on molecular high- vs low-risk individuals.
Study design
The study design is described in detail below (Figure 1).
The following study endpoints were investigated
1. The sensitivity and specificity of theMT-sDNA and FIT using
previously defined thresholds; sensitivity was defined for CRC,
advanced precancerous lesions (AA, ASP, and high-grade
dysplastic lesions) and non-AAs. Specificity was defined for
different control groups (with and without non-neoplastic
and/or nonadvanced polyps).
2. The sensitivity of the MT-sDNA test with FIT using an equal
fixed specificity of 95%; sensitivity was defined and compared
between the 2 tests for CRC and advanced precancerous
lesions (AA, ASP, and high-grade dysplastic lesions).
3. Stool test results in relation to different tumor characteristics,
number of lesions, size, location, morphology, histology, and
dysplasia
4. Stool test results in relation tomolecular-defined low- vs high-
risk AAs.
Data analyses
Statistical analyses were performed using the computing envi-
ronment R version 3.4.4, including the packages pROC, ggplot2,
and epiR (35–37).
All screening participants who underwent a successful colo-
noscopy had a valid FIT result and who provided a stool sample
appropriate for MT-sDNA testing were included in the analysis.
The most advanced colorectal epithelial lesion was used to cate-
gorize screening participants for MT-sDNA analysis. The cate-
gories were controls (including screening participants without
colorectal neoplasia and screening participants with non-AA,
non-ASPs, and other non-neoplastic lesions), advanced pre-
cancerous lesions (including ASP and AA), and CRC. In case of
multiple equivalent advanced precancerous lesions (2 or more
AAs or ASPs), the largest was designated as the index lesion. In
case of co-occurrence of anASP andAAwith the same size, anAA
was considered more advanced than an ASP. In addition, mo-
lecular low-risk and high-risk AAs, as determined by DNA copy
number aberrations (see the section on DNA copy number
analysis), were considered as alternative intermediate endpoints.
Test characteristics were evaluated for advanced precancerous
lesions as a group because there were only 7 cancers present in the
study cohort. Receiver operating characteristic (ROC) analyses
were used to evaluate the overall performance of the MT-sDNA
test and FIT to discriminate advanced neoplasia from controls by
calculating the area under the ROC curve (AUC). To test the
statistical significance of the difference between the AUCs of the
multitarget DNA test vs FIT, theDeLong test with 2000 bootstrap
replications was used.
95% confidence intervals (CIs) for sensitivity and specificity
measures were calculated using an exact binomial test. Given the
fact that the prevalence of CRC is relatively small in the general
population, a high specificity of the test is necessary to reach
a high enough positive predictive value and reduce the number
needed to screen as much as possible. Hence, a fixed and equal
specificity of 95% was used to statistically compare the sensitivity
of the MT-sDNA test with the sensitivity of FIT, for which test
cutoffs were determined by ROC analysis. To test the statistical
significance of the difference of the sensitivity at 95% specificity,
the McNemar test was used.
Evaluating sDNA or FIT results in relation to the number of
lesions per individual or tumor characteristics was performed by
thex2 test or Fisher exact test, in case of low expected counts in the
contingency table. DNA marker results in stool samples were
compared with those in matched tissue samples by Pearson
correlation tests. Comparing the sensitivity of theMT-sDNA test
and FIT in high-risk vs low-risk AA was performed using the
Fisher exact test.
RESULTS
Study population
Whole stool samples for MT-sDNA analysis, FIT results, and
colonoscopy results were available for 1,047 individuals, ac-
counting for 73% (1,047/1,426) of individuals who underwent
colonoscopy within the COCOS trial. Next to missing FIT results
andunsuccessful colonoscopy, someparticipants were notwilling
to collect whole stool samples or not enough stool volume was
obtained for future analysis. MT-sDNA testing was successful in
1,014 of 1,047 evaluated samples (97%). The average age in these
1,014 individuals was 60 years (range 49–75), and 51% (520/
1,014) was men. No differences in age or sex were found between
evaluable and nonevaluable individuals. CRC was present in 7
evaluable individuals (0.7%). Advanced precancerous lesions
were detected in 119 individuals (12%), of which 92 had AA and
27 had with ASP as index lesion. Nonadvanced lesions were
Figure 2. Boxplots showing sDNA test values in the COCOS biomarker
population. Boxplots show first quartile, median, third quartile, and range
of sDNA test values. Dots represent individual data points. The horizontal
dashed lines indicate the predefined threshold for a positive test results as
reported before (*) [ref Imperiale et al., NEJM, 2014], and the adapter
threshold as defined in the current study using a fixed specificity of 95%.
COCOS, COlonoscopy or COlonography for Screening.
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Table 1. Sensitivity and specificity at predefined cutoffs for the MT-sDNA test (threshold 183) and FIT (threshold 50, 75, and 100)
Most advanced
finding Total nr
MT-sDNA test FIT50
MT-sDNA
test vs FIT50 FIT75
MT-sDNA
test vs FIT75 FIT100
MT-sDNA test
vs FIT100
Positive
test (nr)
Sensitivity
(95% CI)
Positive
test (nr)
Sensitivity
(95% CI)
Statistical
difference, P
Positive
test (nr)
Sensitivity
(95% CI)
Statistical
difference, P
Positive
test (nr)
Sensitivity
(95% CI)
Statistical
difference, P
CRC 7 6 85.7% (42.0–100.0) 7 100% (59.0–100.0) 1.0 6 85.7% (42.0–100.0) 1.0 6 85.7% (42.0–100.0) 1.0
Advanced
precancerous
lesions
119 55 46.2% (37.0–55.6) 32 26.9% (19.2–35.8) 0.00001 27 22.6% (15.1–31.6) 0.0000008 27 22.6% (15.1–31.6) 0.0000008
AA 92 44 47.8% (37.3–58.5) 30 32.6% (23.2–43.2) 0.0005 25 27.2% (18.4–37.4) 0.00004 25 27.2% (18.4–37.4) 0.00004
ASP 27 11 40.7% (22.4–61.2) 2 7.4% (0.9–24.3) 0.02 2 7.4% (0.9–24.3) 0.02 2 7.4% (0.9–24.3) 0.02
High-grade
dysplasia
22 8 36.4% (17.2–59.3) 5 22.7% (7.8–45.4) 0.2 4 18.2% (5.2–40.3) 0.2 4 18.2% (5.2–40.3) 0.2
Nonadvanced
adenoma
191 33 17.3% (12.2–23.4) 21 11% (6.9–16 0.04 13 6.8% (3.7–11.4) 0.0001 9 4.7% (2.2–8.8) 0.000003
Most advanced
finding Total nr
MT-sDNA test FIT50
MT-sDNA
test vs FIT50 FIT75
MT-sDNA
test vs FIT75 FIT100
MT-sDNA test
vs FIT100
Positive
test (nr)
Specificity
(95% CI)
Positive
test (nr)
Specificity
(95% CI)
Statistical
difference, P
Positive
test (nr)
Specificity
(95% CI)
Statistical
difference, P
Positive
test (nr)
Specificity
(95% CI)
Statistical
difference, P
Control
individuals,
including non-
neoplastic
and nonadvanced
polypsa
888 97 89.1% (86.8–91.1) 60 93.2% (91.4–94.8) 0.0003 37 95.8% (94.3–97.0) 0.00000000004 25 97.2% (95.9–98.2) 0.0000000000000009
Control
individuals,
including non-
neoplastic
polypsb
697 64 90.8% (88.4–92.9) 39 94.4% (92.4–96.0) 0.004 24 96.6% (94.9–97.8) 0.0000002 16 97.7% (96.3–98.7) 0.0000000002
Control
individuals, no
lesions found at
colonoscopy
527 31 94.1% (91.8–96.0) 28 94.7% (92.4–96.4) 0.7 16 97.0% (95.1–98.3) 0.007 12 98.0% (96.1–98.8) 0.0003
AA, advanced adenoma; ASP, advanced serrated polyp; CI, confidence interval; CRC, colorectal cancer; FIT, fecal immunochemical test; MT-sDNA, multitarget stool DNA.
aIncluding 191 nonadvanced adenoma, 125 nonadvanced serrated polyps, 45 other non-neoplastic lesions, and 527 negative findings with colonoscopy.
bIncluding 125 serrated polyps, 45 other non-neoplastic lesions, and 527 negative findings with colonoscopy.
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detected in 361 individuals (36%), of which 191 had non-AAs,
125 serrated polyps, and 45 other non-neoplastic polyps. In 527
individuals (50%), no lesions were detected (Figure 1).
Multitarget molecular analysis of stool samples
TheMT-sDNA test values in individuals with ASP, AA, and CRC
were significantly higher than in those from control individuals
(P5 0.0007, P5 4.8e-14 and P5 6.0e-05, respectively; Figure 2).
Using the same threshold previously defined for the clinically
validated MT-sDNA test (10) for a positive test result, 6 of 7
individuals with CRC (sensitivity of 85.7%; 95%CI 42.0–100) and
55 of 119 individuals with advanced precancerous lesions (sen-
sitivity of 46.2%; 95% CI 37.0–55.6) tested positive. Of the 92
individuals with AA, 44 were detected (sensitivity of 47.8%; 95%
CI 37.3–58.5). Of the 27 individuals with ASP, 11 were detected
(sensitivity of 40.7%; 95% CI 22.4–61.2) (Table 1).
For the 888 individuals with non-AAs, serrated polyps, other
non-neoplastic polyps, or negative results, specificity of the MT-
sDNA test was 89.1% (95%CI, 86.8–91.1). For the 527 individuals
with negative findings (no lesions found at all), specificity was
94.1% (95% CI 91.8–96.0) (Table 1).
MT-sDNA test compared with FIT
FIT50 was positive in all 7 individuals with CRC. Because the
number of individuals with CRC was too small to perform rele-
vant statistical analysis, we further focused on individuals with
advanced precancerous lesions, i.e., AA and ASP. Sensitivity for
AA andASP using FIT50was 32.6% (95%CI 23.2–43.2) and 7.4%
(95%CI 0.9–24.3), respectively, with specificity of 93.2% (95%CI
91.4–94.8). For the 527 individuals with negative findings (no
lesions found at all), specificity was 94.7% (95% CI 92.4–96.4).
Sensitivity and specificity results for FIT50, FIT75, and FIT100
are shown in Table 1. In addition, the MT-sDNA test detected 24
of 119 advanced precancerous lesions that were not detected by
FIT50 (20.2%), whereas FIT50 detected only 1 of 119 advanced
precancerous lesions that was not detected by the MT-sDNA test
(0.8%) (P , 0.001). The MT-sDNA test detected 10 ASPs that
were not detected by FIT50, whereas FIT50 detected only 1 ASP
that was not detected by the MT-sDNA test (P 5 0.02). The
specificity of single-application FIT was higher than the MT-
sDNA test among individuals without advanced colorectal neo-
plasia (93.2% vs 89.1%, respectively, P5 0.0003), but equal with
the MT-sDNA test for individuals with negative findings only,
e.g., no colorectal lesion of any type (94.7% vs 94.1%, respectively,
P5 0.7).
When comparing the overall performance of the MT-sDNA
test and FIT, i.e., with no predefined cutoffs, the performance of
the MT-sDNA test was significantly better than FIT alone for
discriminating individuals with advanced precancerous lesions
from individuals with non-neoplastic or negative findings (an
ROCAUC of 0.73 for theMT-sDNA test vs an ROCAUC of 0.65
for FIT; P5 0.004) (Figure 3).When comparing the sensitivity of
the MT-sDNA test with FIT using a fixed specificity of 95%
(adapted threshold of 268.5 for MT-sDNA and 65.5 for FIT),
significantly more advanced precancerous lesions were detected
with the MT-sDNA test than with FIT alone (35% vs 25% sen-
sitivity, respectively [P 5 0.01). AAs were detected more often
with the MT-sDNA test compared with FIT alone (39% vs 30%
sensitivity, respectively (P 5 0.06) (Table 2). ASPs were also
detected with a higher sensitivity than by FIT alone (22% vs 7%,
Figure 3. Receiver operating characteristic (ROC) curves of the sDNA test
vs FIT on advanced precancerous lesions (a) subdivided into advanced
adenoma (b) and advanced serrated polyps (c). The continuous and
dashed lines in the ROC curves show the performance of sDNA and FIT,
respectively. AUC, area under the curve; FIT, fecal immunochemical test.
The American Journal of GASTROENTEROLOGY VOLUME 114 | DECEMBER 2019 www.amjgastro.com
C
O
LO
N
Bosch et al.1914
respectively), but this difference did not reach statistical
significance.
Test results in relation to AA characteristics
In total, 119 individualshad at least 1 advancedprecancerous lesion
(AAorASP).Of those, 36had 1 singleAAandno other (non-)AA,
ASP, or CRC. The MT-sDNA test, using the previously reported
cutoff of 183, was more often positive in individuals with multiple
advanced precancerous lesions compared to individuals with only
1 advanced precancerous lesion (69% vs 38%, respectively, P 5
0.005). No statistically significant differences were observed for
FIT50 in detecting individuals with multiple or 1 advanced pre-
cancerous lesion (38% vs 23%, respectively, P5 0.18; Table 3).
For the 36 patients who had only 1 single advanced pre-
cancerous lesion (AA or ASP), test results could be well evaluated
for their associationwith tumor size, location, histology (presence
of villous architecture), dysplasia (presence of high-grade dys-
plasia), and morphology. A positive MT-sDNA test result was
associated to larger lesions (P 5 0.03) and lesions with tubulo-
villous architecture (P5 0.04), whereas a positive FIT50 result did
not show any significant associations for these tumor character-
istics. Both MT-sDNA and FIT50 detected polypoid lesions with
a higher rate than sessile or flat lesions (both tests detected 7/13
[54%] polypoid lesions). Although FIT50 did not detect sessile,
flat, or serrated (ASP) single lesions, MT-sDNA detected 2/18
(11%), 2/5 (40%), and 4/11 (36%) of these lesions, respectively. Six
patients had a single high-grade dysplastic advanced pre-
cancerous lesion (1ASP and 5AAs).Of these 6 lesions, 1 was 1 cm
in size, and 5 were smaller (3–5mm). None of themwere positive
for the MT-sDNA test or for FIT50. All details are provided in
Table 3.
Test results in low- and high-risk AAs
DNA copy number analysis was unsuccessful in 15 evaluated
AAs. This was due to (i) too little DNA, (ii) poor quality of DNA,
and/or (iii) noninterpretable DNA copy analyzes. DNA copy
number aberrations were identified successfully in 93 of 108
evaluated AAs. In total, 20 of 93 AA lesions (from 77 non-CRC
patients) were defined as high risk (22%). From 6 (8%) of these 77
individuals, DNA copy number analysis of 1 or more AAs was
missing. They were excluded from further analyses on high- or
low-risk individuals. From the remaining 71 individuals, 19 had
at least 1 HR adenoma (27%) and therefore considered high risk.
The MT-sDNA test, using the previously reported cutoff of 183,
was positive for 10 of 19 high-risk individuals (sensitivity of 53%,
95%CI 29–76) vs 24 of 52 low-risk individuals (sensitivity of 46%,
95% CI 32–61) (P5 0.8). FIT50 was positive for 9 of 19 high-risk
individuals (sensitivity of 47%, 95%CI 24–71) vs for 18 of 52 low-
risk individuals (sensitivity of 35%, 95%CI 22–49) (P5 0.4). Both
FIT75 and FIT100 were positive for 8 of 19 high-risk individuals
(sensitivity of 42%, 95% CI 20–67) vs for 14 of 52 low-risk
(sensitivity of 27%, 95% CI 16–41) (P5 0.3). Thus, none of MT-
sDNA, FIT50, FIT75, or FIT100 showed significantly different
sensitivities to detect individuals with high-risk adenomas vs
individuals with low-risk adenomas.
DISCUSSION
Accuracy in detecting early CRCs and precancerous lesions is one
of themajor determinants of success of aCRC screening program.
Based on extensive cost-effectiveness evaluation, many organized
screening programs use FIT as a triage test to select individuals for
colonoscopy (38). Although detection of blood in stool has shown
to be successful in reducing mortality from CRC (39–42), sen-
stivity can still be improved. In this study, we evaluated an MT-
sDNA test that previously showed to have great potential to
improve on FIT (10), in an average-risk primary screening pop-
ulation in the Netherlands.
Sensitivity is an important attribute of cancer-screening tests
and crucial for screening programs to reduce death from CRC.
However, given the low prevalence of CRC in the general pop-
ulation, a high specificity of the test is important to reach a high
positive predictive value and reduce the number of participants
Table 2. Sensitivity and specificity at equal fixed specificity of 95%
Most advanced finding Total nr
Multitarget molecular testa FITa Multitarget molecular test vs FIT
Positive test (nr) Sensitivity (95% CI) Positive test (nr) Sensitivity (95% CI) Statistical difference, P
CRC 7 6 85.7% (42.0–100.0) 7 100% (59.0–100.0) 1.0
Advanced precancerous lesions 119 42 35.3% (26.8–44.6) 30 25.2% (17.7–34.0) 0.01
AA 92 36 39.1% (29.1–49.9) 28 30.4% (21.3–40.9) 0.06
ASP 27 6 22.2% (8.6–42.3) 2 7.4% (0.9–24.3) 0.2
High-grade dysplasia 22 5 22.7% (7.8–45.4) 5 22.7% (7.8–45.4) 1.0
Most advanced finding
Total
nr
Multitarget molecular testa FITa
Multitarget molecular test vs
FIT
Positive test
(nr)
Specificity (95%
CI)
Positive test
(nr)
Specificity (95%
CI) Statistical difference, P
Control individuals, including non-
neoplastic and nonadvanced polypsb
888 45 94.9% (93.3–96.3) 45 94.9% (93.3–96.3) 1.0
Negative findings with colonoscopy 527 15 97.2% (95.3–98.4) 19 96.4% (94.4–97.8) 0.5
AA, advanced adenoma; ASP, advanced serrated polyp; CI, confidence interval; CRC, colorectal cancer; FIT, fecal immunochemical test.
aAdapted threshold to reach a fixed specificity of 95%; sDNA 286.5; FIT 65.5.
bIncluding 191 nonadvanced adenoma, 125 nonadvanced serrated polyps, 45 other non-neoplastic lesions, and 527 negative findings with colonoscopy.
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subjected to a follow-up colonoscopy. To compare the single-
application sensitivity of a new screening test with a comparator,
equal specificity for both tests is required, although when a new
screening test has different recommended screening intervals, the
effect of interval will also impact the comparison. In the current
study, we evaluated the single-application performance of theMT-
sDNA test and compared it with single-application performance of
FIT alone with a fixed high specificity of 95% for both tests. In this
setting, the MT-sDNA test showed 10% absolute increase in sen-
sitivity in detecting advanced precancerous lesions compared with
FIT (25%–35%). This is of importance as the best opportunity for
a CRC screening test to be more cost-effective than FIT is by
a higher detection rate for advanced precancerous lesions, rather
than an increased detection of CRC (12,13). The MT-sDNA test
had a significantly higher sensitivity for multiple lesions, larger
lesions, and lesions with tubulovillous architecture. In contrast to
an earlier report (10), in our study, high-grade dysplasia was not
detected with higher sensitivity. Histological revisions of these
lesions revealed that 4 of themdidnot showhigh-gradedysplasia in
newly used slides, suggesting that the size of the previously ob-
served focus of high-grade dysplasiamight have been small in these
lesions. The fact that the lesions themselves were small (3–10mm)
and the focus of high-grade dysplasia might also have been small
could explain why theMT-sDNAdid not detect them. In addition,
the lower sensitivity could also be related to the small number (n5
6) of the high-grade lesions in our study.
ASPs were detected with significant higher sensitivity by the
MT-sDNA test (40.7%) compared with FIT (7.4%). In line with
the knowledge that serrated lesions have high frequencies ofDNA
methylation and CpG Island Methylator Phenotype (43,44), we
found that the single components NDRG4 and BMP3 methyla-
tion of theMT-sDNA tests showed significant increased values in
ASPs as compared to controls, but not forKRASmutations or FIT
(data not shown). These data align with the previous observation
that the current MT-sDNA test is more sensitive for serrated
lesions than FIT (10).
No correlations were found between the MT-sDNA test in
stool and the values of the isolatedDNAcomponents asmeasured
in matched tissue samples. Although such a one-to-one com-
parison cannot be made as other factors, polyclonality of CRC
and sampling issues, size, and other tumor characteristics also
play a role in marker detection, this finding underlines the
complexity of molecular marker detection in stool. It is often not
clear whether the signal stems from the tumor itself, its micro-
environment, or both. Besides, the transit time and stability of the
markers in the gut are unknown factors as well. Moreover, our
Table 3. Stool test results in relation to different tumor characteristics
MT-sDNA test FIT50 FIT75 FIT100
Negative Positive
P
value Negative Positive P value Negative Positive
P
value Negative Positive
P
value
No. of advanced precancerous lesions
(n 5 119 individuals)
1 (n, %) 54 (62) 33 (38) 0.005 67 (77) 20 (23) 0.18 70 (80) 17 (20) 0.27 70 (80) 17 (20) 0.27
.1 (n, %) 10 (31) 22 (69) 20 (63) 12 (38) 22 (69) 10 (31) 22 (69) 10 (31)
Size (n5 36 single lesions)
,10 mm (n, %) 12 (92) 1 (8) 0.03 12 (92) 1 (8) 0.4 12 (92) 1 (8) 0.4 12 (92) 1 (8) 0.4
$10 mm (n, %) 13 (57) 10 (43) 17 (74) 6 (26) 18 (78) 5 (22) 18 (78) 5 (22)
Location (n5 36 single lesions)
Left-sided (n, %) 18 (72) 7 (28) 0.7 18 (72) 7 (28) 0.08 19 (76) 6 (24) 0.1 19 (76) 6 (24) 0.1
Right-sided (n, %) 7 (64) 4 (36) 11 (100) 0 (0) 11 (100) 0 (0) 11 (100) 0 (0)
Morphology (n5 36 single lesions)
Polypoid (n, %) 6 (46) 7 (54) 0.02 6 (46) 7 (54) 0.0004 7 (54) 6 (46) 0.002 7 (54) 6 (46) 0.002
Sessile (n, %) 16 (89) 2 (11) 18 (100) 0 (0) 18 (100) 0 (0) 18 (100) 0 (0)
Flat (n, %) 3 (60) 2 (40) 5 (100) 0 (0) 5 (100) 0 (0) 5 (100) 0 (0)
Histology (n5 36 single lesions)
Tubular (n, %) 10 (91) 1 (9) 0.04 10 (91) 1 (9) 0.06 10 (91) 1 (9) 0.15 10 (91) 1 (9) 0.15
Tubulovillous (n, %) 7 (50) 7 (50) 8 (57) 6 (43) 9 (64) 5 (36) 9 (64) 5 (36)
Serrated (n, %) 7 (88) 1 (13) 8 (100) 0 (0) 8 (100) 0 (0) 8 (100) 0 (0)
Hyperplastic (n, %) 1 (33) 2 (67) 3 (100) 0 (0) 3 (100) 0 (0) 3 (100) 0 (0)
Dysplasia (n5 36 single lesions)
Low grade (n, %) 16 (67) 8 (33) 0.16 17 (71) 7 (29) 0.29 18 (75) 6 (25) 0.3 18 (75) 6 (25) 0.3
High grade (n, %) 6 (100) 0 (0) 6 (100) 0 (0) 6 (100) 0 (0) 6 (100) 0 (0)
FIT, fecal immunochemical test; MT-sDNA, multitarget stool DNA.
P values were calculated using the x2 test or Fisher exact test in case of low sample number per cell.
Bold values denote statistical significance at the P, 0.05 level.
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results suggest that the hemoglobin component in theMT-sDNA
test is of major value and lends support to the idea of improving
FIT by adding the detection ofmolecular markers to hemoglobin,
rather than replacing it (9,45,46).
As it will take at least 10 years to reach the endpoint in CRC
screening, intermediate endpoints are used as an alternative for
evaluating the performance of a screening test and the overall effect
of a screening program. Recently, it has been published that
patients with AA have an increased risk in developing CRC (47).
AA, defined by size and histology of adenomas, is the most widely
used intermediate endpoint. This definition has been adopted since
1987 (48); however, only a minority of AAs show histologic or
molecular features associatedwith high risk of progression (19). As
a result, performance of screening tests may be substantially
underestimated, when evaluated against AAs as intermediate
endpoint. Therefore, we investigated the MT-sDNA test perfor-
mance, when considering the molecular high-risk features,
i.e., specific DNA copy number aberrations in AAs associated with
high risk of progression (18,19,49). DNA copy number alterations
themselves are very challenging tomeasure in stool samples where
a high background of normal and/or bacterial DNA is present;
hence, alternative molecular stool tests are required to detect high-
risk lesions. TheMT-sDNA test that was used in the current study
did not identify individuals with high-risk lesions better when
compared to individuals with only low-risk lesions. This is not an
unexpected finding as the MT-sDNA test includes 2 DNA meth-
ylation markers. DNA methylation is an early event in the de-
velopment of (pre)neoplastic lesions, evenbefore the onset ofDNA
copy number aberrations (50), and hence, DNA methylation
markers in stool are expected to detect early lesions. This is ex-
emplified by the fact that the specificity of the MT-sDNA test was
equal to FIT when only individuals without any lesion were in-
cluded in the control group, but was significantly lower when
individuals with nonadvanced lesions were included in the control
group. Yet, future molecular markers that do correlate with high-
risk adenomas could further improve its performance.
The current study is the first to validate the MT-sDNA test for
CRC screening, in an average-risk population outside the United
States. Moreover, we are the first to investigate whether the MT-
sDNA test, as well as FIT, can detect AAs with a high risk of
progression with a higher sensitivity than AA with low risk. A
limitation to this study is the low number of patients with CRC
because we used an invitational average-risk screening population.
In conclusion, the MT-sDNA test combining DNA methyla-
tion and mutation markers with hemoglobin has a significantly
increased sensitivity for advanced precancerous lesions than FIT
alone at equal specificity, indicating its potential for application in
population screening for CRC.
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